Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
CertaraAugust 13, 2025
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial
Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…
CertaraAugust 13, 2025
Certara Announces D360 25.5 Release, Featuring Dynamic Data Subsets and Enhanced Analytics
D360 v25.5 allows scientists to divide up a dataset into series of compounds & perform…
CertaraAugust 7, 2025
De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator
Watch the on-demand presentation covering how the DIDB® Concomitant Meds Navigator empowers clinical development teams…
CertaraAugust 5, 2025
Model-based meta-analysis (MBMA) at GSK: Real-world impact on strategy and trials
GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…
CertaraJuly 31, 2025
Optimizing Dosing and Regulatory Outcomes in Duchenne Muscular Dystrophy (DMD) Drug Development
Certara supported DMD drug development for Givinostat, helping Italfarmaco with pharmacometric and regulatory strategy.
CertaraJuly 29, 2025
MIDD Strategies for Preclinical and Clinical Translation: A Collaboration Between Clinical Pharmacologists and Modeling Disciplines
Learn how clinical pharmacologists and modeling experts collaborate to improve preclinical-to-clinical translation.
CertaraJuly 29, 2025
